Back to Search Start Over

Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel intensification (DI) for metastatic castration-sensitive prostate cancer (mCSPC).

Authors :
Robin, Gabrielle
Basappa, Naveen S.
North, Scott A.
Ghosh, Sunita
Kolinsky, Michael Paul
Source :
Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, p72-72, 1p
Publication Year :
2023

Details

Language :
English
ISSN :
0732183X
Volume :
41
Database :
Supplemental Index
Journal :
Journal of Clinical Oncology
Publication Type :
Academic Journal
Accession number :
162006964
Full Text :
https://doi.org/10.1200/JCO.2023.41.6_suppl.72